Sökning: WFRF:(Gräslund Torbjörn 1970 ) > Preclinical Evaluat...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05127naa a2200493 4500 | |
001 | oai:DiVA.org:kth-346391 | |
003 | SwePub | |
008 | 240514s2024 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-3463912 URI |
024 | 7 | a https://doi.org/10.3390/ijms250842462 DOI |
040 | a (SwePub)kth | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Deyev, Sergey M.u Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia4 aut |
245 | 1 0 | a Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion |
264 | 1 | b Multidisciplinary Digital Publishing Institute (MDPI),c 2024 |
338 | a print2 rdacarrier | |
500 | a QC 20240516 | |
520 | a Designed ankyrin repeat protein (DARPin) G3 is an engineered scaffold protein. This small (14.5 kDa) targeting protein binds with high affinity to human epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in several cancers. The use of the DARPin G3 for radionuclide therapy is complicated by its high renal reabsorption after clearance via the glomeruli. We tested the hypothesis that a fusion of the DARPin G3 with an albumin-binding domain (ABD) would prevent rapid renal excretion and high renal reabsorption resulting in better tumour targeting. Two fusion proteins were produced, one with the ABD at the C-terminus (G3-ABD) and another at the N-terminus (ABD-G3). Both variants were labelled with 177Lu. The binding properties of the novel constructs were evaluated in vitro and their biodistribution was compared in mice with implanted human HER2-expressing tumours. Fusion with the ABD increased the retention time of both constructs in blood compared with the non-ABD-fused control. The effect of fusion with the ABD depended strongly on the order of the domains in the constructs, resulting in appreciably better targeting properties of [177Lu]Lu-G3-ABD. Our data suggest that the order of domains is critical for the design of targeting constructs based on scaffold proteins. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
653 | a albumin-binding domain (ABD) | |
653 | a DARPin G3 | |
653 | a HER2 | |
653 | a Lutetium-177 ( Lu) 177 | |
653 | a SKOV-3 xenograft | |
653 | a SPECT imaging | |
700 | 1 | a Oroujeni, Maryamu Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden;; Affibody AB, 171 65 Solna, Sweden4 aut |
700 | 1 | a Garousi, Javadu KTH,Proteinvetenskap,Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden4 aut0 (Swepub:kth)u109843g |
700 | 1 | a Gräslund, Torbjörn,d 1970-u KTH,Proteinvetenskap4 aut0 (Swepub:kth)u1dl39rj |
700 | 1 | a Li, Ruonanu KTH,Proteinvetenskap4 aut0 (Swepub:kth)u1zfqnss |
700 | 1 | a Rosly, Alia Hani Bintiu Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden;4 aut |
700 | 1 | a Orlova, Annau Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden;4 aut |
700 | 1 | a Konovalova, Elenau Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia4 aut |
700 | 1 | a Schulga, Alexeyu Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia4 aut |
700 | 1 | a Vorobyeva, Anzhelikau Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden;4 aut |
700 | 1 | a Tolmachev, Vladimiru Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden;4 aut |
710 | 2 | a Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russiab Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden;; Affibody AB, 171 65 Solna, Sweden4 org |
773 | 0 | t International Journal of Molecular Sciencesd : Multidisciplinary Digital Publishing Institute (MDPI)g 25:8q 25:8x 1661-6596x 1422-0067 |
856 | 4 | u https://doi.org/10.3390/ijms25084246y Fulltext |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-346391 |
856 | 4 8 | u https://doi.org/10.3390/ijms25084246 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.